{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:08:50Z","timestamp":1788509330735,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020365","name":"National Foundation for the Centers for Disease Control and Prevention Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"National Institute on Drug Abuse Intramural Research Program","doi-asserted-by":"publisher","award":["1DP1DA060607"],"award-info":[{"award-number":["1DP1DA060607"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030692","name":"National Institute on Drug Abuse Intramural Research Program","doi-asserted-by":"publisher","award":["DP2DA040254"],"award-info":[{"award-number":["DP2DA040254"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI129709-03S1"],"award-info":[{"award-number":["AI129709-03S1"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["AI174276"],"award-info":[{"award-number":["AI174276"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["R01s AI174875"],"award-info":[{"award-number":["R01s AI174875"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.celrep.2026.116954","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:54:55Z","timestamp":1770058495000},"page":"116954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SARS-CoV-2 fusion-peptide-directed antibodies are elicited by natural infection and can mediate broad sarbecovirus neutralization"],"prefix":"10.1016","volume":"45","author":[{"given":"Alex L.","family":"Roederer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia Jung","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larance","family":"Ronsard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lingwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Canaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gravenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1767-3944","authenticated-orcid":false,"given":"Alejandro B.","family":"Balazs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.116954_bib1","unstructured":"COVID - Coronavirus Statistics - Worldometer 2024 https:\/\/www.worldometers.info\/coronavirus\/#google_vignette"},{"key":"10.1016\/j.celrep.2026.116954_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00766-2020","article-title":"Underestimation of COVID-19 mortality during the pandemic","volume":"7","author":"Kung","year":"2021","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.celrep.2026.116954_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010592","article-title":"The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes","volume":"18","author":"Greaney","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2026.116954_bib4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","article-title":"SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","volume":"21","author":"Cox","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.celrep.2026.116954_bib5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.116954_bib6","article-title":"Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016","volume":"2","author":"Starr","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.celrep.2026.116954_bib7","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.116954_bib8","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.116954_bib9","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.116954_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.116954_bib11","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.116954_bib12","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.116954_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","article-title":"Spike mutation D614G alters SARS-CoV-2 fitness","volume":"592","author":"Plante","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.116954_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.116954_bib15","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1016\/j.vaccine.2023.10.051","article-title":"Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86","volume":"41","author":"Lasrado","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2026.116954_bib16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1056\/NEJMc2214314","article-title":"Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1","volume":"388","author":"Miller","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.116954_bib17","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.2.2300740","article-title":"Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023","volume":"29","author":"Jeworowski","year":"2024","journal-title":"Euro Surveill."},{"key":"10.1016\/j.celrep.2026.116954_bib18","article-title":"Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity","volume":"5","author":"Roederer","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.celrep.2026.116954_bib19","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.116954_bib20","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.15585\/mmwr.mm7148e1","article-title":"Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection \u2014 Increasing Community Access to Testing Program, United States, September\u2013November 2022","volume":"71","author":"Link-Gelles","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.celrep.2026.116954_bib21","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S1473-3099(22)00692-2","article-title":"BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5","volume":"22","author":"Tartof","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2026.116954_bib22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1473-3099(23)00070-1","article-title":"Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2026.116954_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/vaccines12020118","article-title":"Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals \u226512 Years Old: A Phase 2\/3 Trial","volume":"12","author":"Gayed","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.celrep.2026.116954_bib24","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S1473-3099(23)00746-6","article-title":"Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study","volume":"24","author":"Hansen","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2026.116954_bib25","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1093\/infdis\/jiae067","article-title":"Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines","volume":"230","author":"Chalkias","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.celrep.2026.116954_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm7304a2","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.celrep.2026.116954_bib27","unstructured":"(2024). Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024. FDA."},{"key":"10.1016\/j.celrep.2026.116954_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41541-024-01016-6","article-title":"Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera","volume":"9","author":"Xu","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.celrep.2026.116954_bib29","article-title":"Virological characteristics of the SARS-CoV-2 KP.2 variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2026.116954_bib30","unstructured":"GISAID Initiative https:\/\/www.epicov.org\/epi3\/frontend#b40c."},{"key":"10.1016\/j.celrep.2026.116954_bib32","first-page":"1","article-title":"Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies. Pathog","volume":"10","author":"Planas","year":"2024","journal-title":"Immun"},{"key":"10.1016\/j.celrep.2026.116954_bib33","unstructured":"Vaccines and Related Biological Products Advisory Committee May 16, 2024 Meeting Announcement - 05\/16\/2024 (2024). FDA. https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/vaccines-and-related-biological-products-advisory-committee-may-16-2024-meeting-announcement."},{"key":"10.1016\/j.celrep.2026.116954_bib34","series-title":"Influenza Vaccines for the Future","first-page":"425","article-title":"Economic Implications of Influenza and Influenza Vaccine","author":"Walsh","year":"2011"},{"key":"10.1016\/j.celrep.2026.116954_bib35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10058-024-00363-z","article-title":"Quantifying the Social Value of a Universal COVID-19 Vaccine and Incentivizing Its Development","volume":"28","author":"Glennerster","year":"2024","journal-title":"Review Econ. Design"},{"key":"10.1016\/j.celrep.2026.116954_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41586-021-03807-6","article-title":"SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape","volume":"597","author":"Starr","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.116954_bib37","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41467-024-45050-3","article-title":"Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.116954_bib38","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1126\/science.abo7896","article-title":"Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution","volume":"377","author":"Starr","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.116954_bib39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.chom.2022.10.010","article-title":"Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses","volume":"31","author":"Dacon","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.celrep.2026.116954_bib40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.immuni.2023.02.005","article-title":"Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease","volume":"56","author":"Zhou","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.116954_bib41","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.abj3321","article-title":"Broad betacoronavirus neutralization by a stem helix\u2013specific human antibody","volume":"373","author":"Pinto","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.116954_bib42","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41467-021-21968-w","article-title":"A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies","volume":"12","author":"Wang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.116954_bib43","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41564-022-01155-3","article-title":"Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2","volume":"7","author":"Sun","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.celrep.2026.116954_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade0958","article-title":"Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein","volume":"8","author":"Bianchini","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.celrep.2026.116954_bib45","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.abq3773","article-title":"Broadly neutralizing antibodies target the coronavirus fusion peptide","volume":"377","author":"Dacon","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.116954_bib46","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.abq2679","article-title":"ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies","volume":"377","author":"Low","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.116954_bib47","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3390\/v14092061","article-title":"Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2","volume":"14","author":"Farrell","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.celrep.2026.116954_bib48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.chom.2021.02.003","article-title":"Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies","volume":"29","author":"Greaney","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.celrep.2026.116954_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi9915","article-title":"Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection","volume":"13","author":"Greaney","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2026.116954_bib50","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51230","article-title":"The human coronavirus HCoV-229E S-protein structure and receptor binding","volume":"8","author":"Li","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.celrep.2026.116954_bib51","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1128\/JVI.77.7.4435-4438.2003","article-title":"Human Coronavirus 229E: Receptor Binding Domain and Neutralization by Soluble Receptor at 37\u00b0C","volume":"77","author":"Breslin","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.116954_bib52","doi-asserted-by":"crossref","first-page":"9379","DOI":"10.1128\/JVI.01277-13","article-title":"The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies","volume":"87","author":"Mou","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.116954_bib53","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/cr.2013.92","article-title":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4","volume":"23","author":"Wang","year":"2013","journal-title":"Cell Res."},{"key":"10.1016\/j.celrep.2026.116954_bib54","doi-asserted-by":"crossref","first-page":"W344","DOI":"10.1093\/nar\/gkw408","article-title":"ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules","volume":"44","author":"Ashkenazy","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2026.116954_bib55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41541-021-00393-6","article-title":"Scientific rationale for developing potent RBD-based vaccines targeting COVID-19","volume":"6","author":"Kleanthous","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.celrep.2026.116954_bib56","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.116954_bib57","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.116954_bib58","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41467-020-16638-2","article-title":"Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients","volume":"11","author":"Poh","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.116954_bib59","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.116954_bib60","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection","volume":"7","author":"Yang","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.celrep.2026.116954_bib61","doi-asserted-by":"crossref","first-page":"eadf4100","DOI":"10.1126\/scitranslmed.adf4100","article-title":"Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2","volume":"15","author":"Stewart-Jones","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2026.116954_bib62","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41467-024-45404-x","article-title":"Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge","volume":"15","author":"Hsieh","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.116954_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104341","article-title":"Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses","volume":"86","author":"Halfmann","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.celrep.2026.116954_bib64","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1126\/science.aae0474","article-title":"Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody","volume":"352","author":"Kong","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.116954_bib65","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.1016\/j.cell.2024.10.003","article-title":"Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.116954_bib66","unstructured":"WHO chief declares end to COVID-19 as a global health emergency | UN News (2023). https:\/\/news.un.org\/en\/story\/2023\/05\/1136367."},{"key":"10.1016\/j.celrep.2026.116954_bib67","unstructured":"Statement on the fifteenth meeting of the IHR Emergency Committee on the COVID-19 pandemic (2005) https:\/\/www.who.int\/news\/item\/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic."},{"key":"10.1016\/j.celrep.2026.116954_bib68","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/1087057112465184","article-title":"Affordable luciferase reporter assay for cell-based high-throughput screening","volume":"18","author":"Siebring-van Olst","year":"2013","journal-title":"J. Biomol. Screen"}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221112472600032X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221112472600032X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:55:13Z","timestamp":1777092913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221112472600032X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S221112472600032X"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.116954","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 fusion-peptide-directed antibodies are elicited by natural infection and can mediate broad sarbecovirus neutralization","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.116954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116954"}}